Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Viewpoint

  • 150 Articles
  • 0 Posts
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 14
  • 15
  • Next →
Guild-based approach for mitigating information loss and distortion issues in microbiome analysis
Liping Zhao, … , Guojun Wu, Naisi Zhao
Liping Zhao, … , Guojun Wu, Naisi Zhao
Published September 3, 2024
Citation Information: J Clin Invest. 2024;134(17):e185395. https://doi.org/10.1172/JCI185395.
View: Text | PDF

Guild-based approach for mitigating information loss and distortion issues in microbiome analysis

  • Text
  • PDF
Abstract

Authors

Liping Zhao, Guojun Wu, Naisi Zhao

×

The cancer-associated secretory phenotype: a new frontier in targeted therapeutics
Xiaochao Tan, … , Shike Wang, Jonathan M. Kurie
Xiaochao Tan, … , Shike Wang, Jonathan M. Kurie
Published September 3, 2024
Citation Information: J Clin Invest. 2024;134(17):e182652. https://doi.org/10.1172/JCI182652.
View: Text | PDF

The cancer-associated secretory phenotype: a new frontier in targeted therapeutics

  • Text
  • PDF
Abstract

Authors

Xiaochao Tan, Guan-Yu Xiao, Priyam Banerjee, Shike Wang, Jonathan M. Kurie

×

Status check: next-generation sequencing for infectious-disease diagnostics
Kyle G. Rodino, Patricia J. Simner
Kyle G. Rodino, Patricia J. Simner
Published February 15, 2024
Citation Information: J Clin Invest. 2024;134(4):e178003. https://doi.org/10.1172/JCI178003.
View: Text | PDF

Status check: next-generation sequencing for infectious-disease diagnostics

  • Text
  • PDF
Abstract

Next-generation sequencing (NGS) applications for the diagnostics of infectious diseases has demonstrated great potential with three distinct approaches: whole-genome sequencing (WGS), targeted NGS (tNGS), and metagenomic NGS (mNGS, also known as clinical metagenomics). These approaches provide several advantages over traditional microbiologic methods, though challenges still exist.

Authors

Kyle G. Rodino, Patricia J. Simner

×

Molecular and cellular mechanisms underlying the failure of mitochondrial metabolism drugs in cancer clinical trials
Karthik Vasan, Navdeep S. Chandel
Karthik Vasan, Navdeep S. Chandel
Published February 1, 2024
Citation Information: J Clin Invest. 2024;134(3):e176736. https://doi.org/10.1172/JCI176736.
View: Text | PDF

Molecular and cellular mechanisms underlying the failure of mitochondrial metabolism drugs in cancer clinical trials

  • Text
  • PDF
Abstract

Authors

Karthik Vasan, Navdeep S. Chandel

×

Keeping translational research grounded in human biology
Saptarsi M. Haldar
Saptarsi M. Haldar
Published January 16, 2024
Citation Information: J Clin Invest. 2024;134(2):e178332. https://doi.org/10.1172/JCI178332.
View: Text | PDF

Keeping translational research grounded in human biology

  • Text
  • PDF
Abstract

Authors

Saptarsi M. Haldar

×

Building reproducible bridges to cross the “valley of death”
Timothy M. Errington
Timothy M. Errington
Published January 2, 2024
Citation Information: J Clin Invest. 2024;134(1):e177383. https://doi.org/10.1172/JCI177383.
View: Text | PDF

Building reproducible bridges to cross the “valley of death”

  • Text
  • PDF
Abstract

Authors

Timothy M. Errington

×

Human brown fat and metabolic disease: a heated debate
Rana K. Gupta
Rana K. Gupta
Published December 1, 2023
Citation Information: J Clin Invest. 2023;133(23):e176678. https://doi.org/10.1172/JCI176678.
View: Text | PDF

Human brown fat and metabolic disease: a heated debate

  • Text
  • PDF
Abstract

Authors

Rana K. Gupta

×

Human brown adipose tissue is not enough to combat cardiometabolic diseases
André C. Carpentier, Denis P. Blondin
André C. Carpentier, Denis P. Blondin
Published December 1, 2023
Citation Information: J Clin Invest. 2023;133(23):e175288. https://doi.org/10.1172/JCI175288.
View: Text | PDF

Human brown adipose tissue is not enough to combat cardiometabolic diseases

  • Text
  • PDF
Abstract

Authors

André C. Carpentier, Denis P. Blondin

×

Does activating brown fat contribute to important metabolic benefits in humans? Yes!
Aaron M. Cypess
Aaron M. Cypess
Published December 1, 2023
Citation Information: J Clin Invest. 2023;133(23):e175282. https://doi.org/10.1172/JCI175282.
View: Text | PDF

Does activating brown fat contribute to important metabolic benefits in humans? Yes!

  • Text
  • PDF
Abstract

Authors

Aaron M. Cypess

×

FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches
Peter-James H. Zushin, … , Souhrid Mukherjee, Joseph C. Wu
Peter-James H. Zushin, … , Souhrid Mukherjee, Joseph C. Wu
Published November 1, 2023
Citation Information: J Clin Invest. 2023;133(21):e175824. https://doi.org/10.1172/JCI175824.
View: Text | PDF

FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI/ML-based approaches

  • Text
  • PDF
Abstract

Authors

Peter-James H. Zushin, Souhrid Mukherjee, Joseph C. Wu

×
  • ← Previous
  • 1
  • 2
  • 3
  • …
  • 14
  • 15
  • Next →

No posts were found with this tag.

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts